Why is "Cel" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-20 23:03:56
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Cel entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-03-20 and was most recently seen on 2026-03-20.
Wikipedia Overview
A cel, short for celluloid, is a transparent sheet on which objects are drawn or painted for traditional, classical, hand-drawn animation. Actual celluloid was used during the first half of the 20th century. Since it was flammable and dimensionally unstable, celluloid was largely replaced by cellulose acetate and polyester. With the advent of computer-assisted animation production, the use of cels has become obsolete in major productions. Walt Disney Animation Studios stopped using cels in 1990, when Computer Animation Production System (CAPS) replaced this element in their animation process. In the next decade and a half, other animation studios phased cels out as well in favor of digital ink and paint.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Mar Y Cel catch up with us to to talk all things Ibiza and about their recent single 'Thrill Me' - Beatportal
-
CEL-SCI Reports Fiscal Second Quarter 2026 Results - BioSpace
-
Evaluating CAR-T Miv-Cel in Myasthenia Gravis - Neurology Live
-
Announcing CEL-expr-python: the Common Expression Language in Python, now open source - blog.google
-
ALPHA3 Explores LBCL First-Line Consolidation With Off-the-Shelf Cema-Cel - Targeted Oncology
-
FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations - OncLive
-
Center for Engaged Learning (CEL) Student Scholars call for applications - Elon University
-
AAN 2026: Phase I/II success for rese-cel in gMG signals potential amid competition - Clinical Trials Arena
-
CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial - Nature
-
CEL-SCI Announces Closing of Public Offering - Business Wire
-
CABA: Rese-cel delivers durable, safe, and scalable CAR T therapy for autoimmune diseases - TradingView
-
New study finds anti-CD19 CAR-T therapy, Zorpo-cel, safe and effective treatment for people with systemic lupus erythematosus - Lupus Foundation of America
-
Assessing CAR-T Miv-Cel in Myasthenia Gravis: Srikanth Muppidi, MD - Neurology Live
-
FDA Approves Brexu-Cel for Relapsed/Refractory MCL - OncLive
-
FDA Grants Full Approval to Brexu-Cel in R/R Mantle Cell Lymphoma - Targeted Oncology
-
Assessing CAR-T Miv-Cel in Stiff Person Syndrome - Neurology Live
-
Sofi-Cel Earns FDA Breakthrough Therapy Designation in Heavily Pretreated R/R T-ALL and T-LBL - OncLive
-
High Response With Brexu-Cel in R/R MCL: Data Driving FDA Approval - Targeted Oncology
-
Anito-Cel Emerges as Potential Novel Option in R/R Multiple Myeloma - OncLive
-
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL - OncLive
-
ASH 2025: Arcellx and Gilead’s Anito-cel challenges CAR-T market in R/R MM - Clinical Trials Arena
-
Why Did CEL-SCI Stock Plunge After Its Latest Offering - Kavout
-
Cel-Sci Corp Files For Offering Of 6 Million Shares Of Common Stock- SEC Filing - TradingView
-
Anito-Cel Yields Enduring Efficacy in Relapsed/Refractory Multiple Myeloma - CancerNetwork
-
CEL-SCI Corporation Announces Pricing of Public Offering - Business Wire
-
Patients Report Exa-cel for SCD Brings Array of Quality-of-Life Improvements - Docwire News
-
Reni-cel Gene Therapy for Sickle Cell Disease - Cleveland Clinic
-
EU Approves Liso-Cel in R/R MCL With ≥ 2 Prior Lines of Systemic Therapy - CancerNetwork
-
[EFFECT] CEL SCI CORP SEC Filing - Stock Titan
-
Obe-Cel Displays Real-World Safety Benefits, Similar Efficacy to Brexu-Cel in R/R ALL - OncLive
-
CEL-SCI Reports Fiscal First Quarter 2026 Results - Yahoo Finance
-
Vispa-Cel Shows Comparable Efficacy, Durability to Autologous CAR T-Cell Therapy in R/R B-Cell NHL - OncLive
-
Real-World Analysis Reveals Favorable Outcomes With Liso-Cel in Chronic Lymphocytic Leukemia - OncLive
-
Cellectis leukemia, lymphoma cell therapies hit EHA 2026 stage - Stock Titan
-
Cilta-Cel Generates 100% ORR, MRD-Negativity Rate in High-Risk Smoldering Myeloma - OncLive
-
Axi-Cel’s QOL Gains in R/R LBCL Extend to Transplant-Ineligible Patients - Targeted Oncology
-
Allogeneic CAR T Cema-Cel Boosts MRD Clearance in LBCL - Targeted Oncology
-
Later-Line Liso-Cel Yields Efficacy Benefits vs Real-World SOC for R/R Mantle Cell Lymphoma - OncLive
-
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma - OncLive
-
Anito-Cel Yields Durable Responses With Manageable Safety in R/R Multiple Myeloma - OncLive
-
Celtic 3-1 Hearts (16 May, 2026) Game Analysis - ESPN
-
TRANSFORM long-term follow-up: Liso-cel for 2L R/R LBCL - Lymphoma Hub
-
Liso-Cel Drives Durable Longer-Term Benefit in R/R Follicular Lymphoma - OncLive
-
‘A Charlie Brown Christmas’ Sets New ‘Peanuts’ Cel Record at Heritage Auctions - Animation Magazine
-
Safety and efficacy of hemobeglogene autotemcel(hemo-cel) gene therapy in five patients with transfusion-dependent β-thalassemia - ScienceDirect.com
-
Prince Radu visits 'Alexandru cel Bun' Military Academy in Chisinau - Agerpres
-
ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch - Fierce Biotech
-
Cabaletta Bio (NASDAQ: CABA) unveils new rese-cel autoimmune and PC-free data - Stock Titan
-
Atara Secures FDA Path To Resubmit Tab‑cel, Stock Rallies - Hoodline
-
Dr Valtis on Real-World Outcomes Following Treatment With Obe-Cel and Brexu-Cel in R/R ALL - OncLive
-
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia - Business Wire
-
CEL-SCI Reports Fiscal 2025 Results - Yahoo Finance
-
Real-World Data Highlight Favorable Responses to Liso-Cel for R/R CLL - The American Journal of Managed Care® (AJMC®)
-
Exploring the Novel CAR T-Cell Therapy Anito-Cel in Multiple Myeloma - OncLive
-
Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma - Targeted Oncology
-
Brexu-Cel Secures Full FDA Approval in R/R MCL: Reflections From ZUMA-2 - Targeted Oncology
-
Preliminary Data Support Further Exploration of Obe-Cel in Pediatric R/R B-ALL - OncLive
-
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma - OncLive
-
FDA Removes Use Limitations for Axi-Cel in R/R PCNSL - Hematology Advisor
-
ZUMA-2 Trial Design: Evolution of Cohorts and Brexu-Cel Dosing - Targeted Oncology
-
ASH 2025: CAR T cell therapy shows promising Phase II trial results in multiple myeloma - UT MD Anderson
-
Phase 2 Analysis Shows Deep, Durable Responses with Liso-Cel Across MZL Subtypes - Targeted Oncology
-
Highlighting Comparative Liso-cel Efficacy Across Multiple LBCL Domains - CancerNetwork
-
Cema-Cel Improves MRD Clearance as First-Line Consolidation in Large B-Cell Lymphoma - OncLive
-
Katie Baker selected as the 2026-28 Center for Engaged Learning (CEL) Scholar - Elon University
-
Phase 1 CAR-T for lymphoma, myeloma set for EHA 2026 talks - Stock Titan
-
Acalabrutinib/Rituximab Followed by Brexu-Cel Drives Responses in Untreated High-Risk Mantle Cell Lymphoma - OncLive
-
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma - Targeted Oncology
-
Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma - The ASCO Post
-
Lower CRS Enables Outpatient Use of Anito-Cel in R/R Multiple Myeloma - CancerNetwork
-
High-Grade Toxicity of Brexu-Cel in R/R B-ALL Persists in Real-World Use - Targeted Oncology
-
Zevor-Cel Shows Long-Term Efficacy in Small R/R Multiple Myeloma Population - CancerNetwork
-
FDA Approves Marne-Cel, First Stem Cell-Based Gene Therapy for Pediatric Patients With LAD-I - Pharmacy Times
-
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue - PR Newswire
-
FDA Approves Liso-Cel for Relapsed/Refractory Marginal Zone Lymphoma - OncLive
-
CEL-SCI prices $7.2M public offering at $1.20 per share - Investing.com
-
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story - Yahoo Finance
-
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting - Yahoo Finance
-
Novel variation in the CEL gene causing impaired fasting glucose in a Chinese pediatric patient: case report and literature review - Frontiers
-
Dr Nadeem on Efficacy and Safety of Arlo-Cel for R/R Myeloma - OncLive
-
Real-World CAR-T Comparisons: Axi-cel vs Liso-cel in 2L LBCL - CancerNetwork
-
Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside - Yahoo Finance
-
Gilead to Acquire Arcellx for $7.8B, Adding Anito-Cel to Cancer Pipeline - Genetic Engineering and Biotechnology News
-
Return to the cel shaded Great Sea of Hyrule - The Brothers Brick
-
Bridging Outcome, ALC Linked to Parkinsonism With Cilta-Cel in Multiple Myeloma - Targeted Oncology
-
Gilead–Arcellx Deal: Up to $7.8B for Anito-cel CAR-T in Multiple Myeloma - Oncodaily
-
How Liso-Cel Is Shifting the Treatment Paradigm of Marginal Zone Lymphoma - Targeted Oncology
-
Long-Term Data Affirm Efficacy of Zevor-Cel in R/R Myeloma - OncLive
-
Dr Denlinger on the Real-World Use of Axi-Cel and Liso-Cel in R/R LBCL - OncLive
-
Physician Views Preview: Does ASH update position Gilead and Arcellx's anito-cel as a potential Carvykti-killer? - FirstWord Pharma
-
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease - The New England Journal of Medicine
-
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA - Yahoo Finance
-
CEL Critical Power Opens New Manufacturing Facility in James City County - Williamsburg Yorktown Daily
-
Rabi Hanna, MD, on Evaluating Gene Editing Therapy Reni-Cel for Severe Sickle Cell Disease - CGTLive®
-
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma - OncLive
-
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025 - PR Newswire
-
CEL SCI (CVM) CEO awarded 1,682 shares of common stock - Stock Titan
-
Earlier Cilta-Cel Improves Myeloma Outcomes Via Enhanced Immune Fitness - Targeted Oncology
-
Long-Term Cilta-Cel Follow-Up Shows Curative Potential in Pretreated Multiple Myeloma - CancerNetwork
-
In China, Phase 2 Study of Relma-Cel in R/R MCL Finds Durable Responses - The American Journal of Managed Care® (AJMC®)
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.